Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients-Reference-Cited by-同舟云学术

Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients

Published:2016-01 Issue:1 Volume:44 Page:3-13
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Shin Ho-Jin,Yoon Dok Hyun,Lee Ho Sup,Oh Sung Yong,Yang Deok Hwan,Kang Hye Jin,Chong So Young,Park Yong,Do YoungRok,Lim Sung-Nam,Jo Jae-Cheol,Lee Won Sik,Chung Joo-Seop

Funder

Pusan National University Hospital

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference19 articles.

1. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era;Ziepert;J Clin Oncol,2010

2. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP;Sehn;Blood,2007

3. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2012

4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

5. Rituximab improves the treatment results of DHAP–VIM–DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial;Vellenga;Blood,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation;BMC Cancer;2024-08-13

2. Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma;Clinical and Experimental Medicine;2023-04-22

3. The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma;Cancer Reports;2023-02-28

4. Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis;Annals of Hematology;2020-04-13

5. Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients;Oncotarget;2017-04-21